IMpower010: Updated overall survival and safety results from Asian patients in a Phase III study of adjuvant atezolizumab vs best supportive care in resected stage IB-IIIA NSCLC

被引：2
|
作者：
Wang, Jie
Fan, Yun
Fang, Jian
He, Jianxing
Liu, Yunpeng
Tao, Min
Altorki, Nasser
Felip, Enriqueta
Wakelee, Heather
Vallieres, Eric
Belleli, Rossella
McNally, Virginia
Bennett, Elizabeth
Gitlitz, Barbara J.
Zhou, Caicun
机构：
来源：
CANCER RESEARCH | 2024年 / 84卷 / 07期
关键词：
D O I：
10.1158/1538-7445.AM2024-CT239
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
CT239
引用
收藏
页数：2
相关论文
共 50 条
  • [1] IMpower010: results from Asian patients in a phase 3 study of adjuvant atezolizumab in resected stage IB-IIIA NSCLC
    Kenmotsu, Hirotsugu
    Zhou, Caicun
    Altorki, Nasser
    Felip, Enriqueta
    Vallieres, Eric
    Sugawara, Shunichi
    Sakai, Hiroshi
    Saito, Haruhiro
    Tao, Min
    Kawaguchi, Koji
    Liu, Yunpeng
    Yu, Chong-Jen
    Wu, Qiong
    Lin, Huang
    Wu, Fan
    Bennett, Elizabeth
    Mcnally, Virginia
    Gitlitz, Barbara
    Wakelee, Heather
    ANNALS OF ONCOLOGY, 2022, 33 : S464 - S464
  • [2] IMpower010: Sites of relapse and subsequent therapy from a phase III study of atezolizumab vs best supportive care after adjuvant chemotherapy in stage IB-IIIA NSCLC
    Felip, E.
    Vallieres, E.
    Zhou, C.
    Wakelee, H.
    Bondarenko, I.
    Sakai, H.
    Saito, H.
    Ursol, G.
    Kawaguchi, K.
    Liu, Y.
    Levchenko, E.
    Kislov, N.
    Reck, M.
    Liersch, R.
    McNally, V. A.
    Zhu, Q.
    Ding, B.
    Bennett, E.
    Gitlitz, B.
    Altorki, N. K.
    ANNALS OF ONCOLOGY, 2021, 32 : S1319 - S1319
  • [3] IMpower010:Overall Survival Interim Analysis of a Phase III Study of Atezolizumab vs Best Supportive Care in Resected NSCLC
    Wakelee, H.
    Altorki, N.
    Felip, E.
    Vallieres, E.
    Vynnychenko, I. O.
    Akopov, A.
    Martinez-Marti, A.
    Chella, A.
    Bondarenko, I.
    Sugawara, S.
    Fan, Y.
    Kenmotsu, H.
    Chen, Y. -M.
    Deng, Y.
    Wu, F.
    McNally, V.
    Bennett, E.
    Gitlitz, B. J.
    Zhou, C.
    JOURNAL OF THORACIC ONCOLOGY, 2022, 17 (09) : S2 - S2
  • [4] IMpower010: A Phase III Study of Atezolizumab vs Best Supportive Care Following Adjuvant Chemotherapy in Completely Resected NSCLC
    Felip, E.
    Wakelee, H.
    Vallieres, E.
    Zhou, C.
    Zuo, Y.
    Xia, F.
    Sandler, A.
    Altorki, N.
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S2398 - S2399
  • [5] IMpower010: Biomarkers of disease-free survival (DFS) in a phase III study of atezolizumab (atezo) vs best supportive care (BSC) after adjuvant chemotherapy in stage IB-IIIA NSCLC
    Zhou, C.
    Das Thakur, M.
    Srivastava, M. K.
    Zou, W.
    Xu, H.
    Ballinger, M.
    Felip, E.
    Wakelee, H.
    Altorki, N. K.
    Reck, M.
    Liersch, R.
    Kryzhanivska, A.
    Harada, M.
    Tanaka, H.
    Hamm, J.
    McCune, S.
    McNally, V.
    Bennett, E.
    Gitlitz, B.
    Novello, S.
    ANNALS OF ONCOLOGY, 2021, 32 : S1374 - S1374
  • [6] IMpower010: Primary results of a phase III global study of atezolizumab versus best supportive care after adjuvant chemotherapy in resected stage IB-IIIA non-small cell lung cancer (NSCLC).
    Wakelee, Heather A.
    Altorki, Nasser K.
    Zhou, Caicun
    Csoszi, Tibor
    Vynnychenko, Ihor O.
    Goloborodko, Oleksandr
    Luft, Alexander
    Akopov, Andrey
    Martinez-Marti, Alex
    Kenmotsu, Hirotsugu
    Chen, Yuh-Min
    Chella, Antonio
    Sugawara, Shunichi
    Gitlitz, Barbara J.
    Bennett, Elizabeth
    Wu, Fan
    Yi, Jing
    Deng, Yu
    McCleland, Mark
    Felip, Enriqueta
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [7] IMpower010: Characterization of Stage IB-IIIA NSCLC Patients by Type and Extent of Therapy Prior to Adjuvant Atezolizumab
    Altorki, N.
    Felip, E.
    Zhou, C.
    Vallieres, E.
    Moiseyenko, V.
    Smolin, A.
    Rittmeyer, A.
    Vereshchako, R.
    Perol, M.
    Schutte, W.
    Fang, J.
    Tao, M.
    Teixeira, E.
    Kim, Y.
    Gitlitz, B.
    Bennett, E.
    Mcnally, V.
    Wu, F.
    Deng, Y.
    Wakelee, H.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (10) : S845 - S846
  • [8] IMpower010: Final disease-free survival (DFS) and second overall survival (OS) interim results after ≥5 years of follow up of a phase III study of adjuvant atezolizumab vs best supportive care in resected stage IB-IIIA non-small cell lung cancer (NSCLC).
    Wakelee, Heather A.
    Altorki, Nasser K.
    Zhou, Caicun
    Csoszi, Tibor
    Vynnychenko, Ihor O.
    Goloborodko, Oleksandr
    Rittmeyer, Achim
    Reck, Martin
    Martinez-Marti, Alex
    Kenmotsu, Hirotsugu
    Chen, Yuh-Min
    Chella, Antonio
    Sugawara, Shunichi
    Fu, Chenqi
    Ballinger, Marcus
    Deng, Yu
    Srivastava, Minu K.
    Bennett, Elizabeth
    Gitlitz, Barbara Jenifer
    Felip, Enriqueta
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (17_SUPPL) : LBA8035 - LBA8035
  • [9] Adjuvant atezolizumab in Japanese patients with resected stage IB-IIIA non-small cell lung cancer (IMpower010)
    Kenmotsu, Hirotsugu
    Sugawara, Shunichi
    Watanabe, Yasutaka
    Saito, Haruhiro
    Okada, Morihito
    Chen-Yoshikawa, Toyofumi Fengshi
    Ohe, Yuichiro
    Nishio, Wataru
    Nakagawa, Shizuka
    Nagao, Haruka
    CANCER SCIENCE, 2022, 113 (12) : 4327 - 4338
  • [10] IMpower010: Phase III Study of Atezolizumab vs BSC after Adjuvant Chemotherapy in Patients with Completely Resected NSCLC
    Wakelee, Heather
    Altorki, Nasser
    Vallieres, Eric
    Zhou, Caicun
    Zuo, Yunxia
    Howland, Michael
    Xia, Fan
    Hoang, Tien
    Sandler, Alan
    Felip, Enriqueta
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (01) : S1305 - S1305
12345